19672-63-0

Basic information

• Product Name: 1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one
• CAS NO: 19672-63-0
• Molecular Formula: C₁₆H₁₃ClO
• Molecular Weight: 256.7268
• Mol File: 19672-63-0.mol
• Article Data: 49

Chemical Properties

• Boiling Point: 401.6°C at 760 mmHg
• Flash Point: 227°C
• Density: 1.177g/cm³
• Vapor Pressure: 1.16E-06mmHg at 25°C
• Refractive Index: 1.622
• CAS DataBase Reference: 1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one(19672-63-0)
• EPA Substance Registry System: 1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one(19672-63-0)

Safety Data

• Hazardous Substances Data: 19672-63-0(Hazardous Substances Data)

Usage

Description

1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one, commonly referred to as a product of the Claisen-Schmidt condensation, is a yellow solid that plays a significant role in organic chemistry synthesis. This α,β-unsaturated ketone is synthesized through the condensation of 4-chlorobenzaldehyde and 4-methylbenzaldehyde in the presence of a base like sodium ethoxide. Its unique structure, featuring versatile reactivity and functional groups, positions it as a crucial building block for the development of novel compounds with potential applications in the pharmaceutical and industrial sectors.

Uses

Used in Pharmaceutical Synthesis:
1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one is used as a key intermediate in the pharmaceutical industry for the synthesis of various drugs. Its unique structure and functional groups allow for the creation of new compounds with potential therapeutic properties.
Used in Fine Chemicals Production:
In the fine chemicals sector, 1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one serves as an essential intermediate. Its versatile reactivity enables the development of specialty chemicals that can be utilized in a wide range of applications, from fragrances to dyes and other high-value products.
Used in Organic Chemistry Research:
1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one is also employed in organic chemistry research as a model compound for studying various reaction mechanisms and exploring new synthetic pathways. Its unique structure provides researchers with valuable insights into the behavior of α,β-unsaturated ketones and their potential applications in chemical synthesis.

Upstream product

• 104-87-0 4-methyl-benzaldehyde 
• 99-91-2 para-chloroacetophenone 
• 101272-32-6 2,3-dibromo-1-(4-chloro-phenyl)-3-p-tolyl-propan-1-one 
• 123-54-6 acetylacetone 
• 109-77-3 malononitrile 
• 37620-37-4 (E)-4-chloro-4'-methylchalcone 
• 19672-63-0 (2E)-1-(4-chlorophenyl)-3-(4-methylphenyl)prop-2-en-1-one 
• 104-88-1 4-chlorobenzaldehyde 
• 122-00-9 para-methylacetophenone 
• 166823-95-6 (E)-3-(4-chlorophenyl)-1-(p-tolyl)prop-2-en-1-ol 
• 166824-02-8 (E)-1-(4-chlorophenyl)-3-(p-tolyl)prop-2-en-1-ol 
• 622-97-9 1-ethenyl-4-methylbenzene 
• 7099-88-9 4-chlorophenylglyoxylic acid 

Downstream Products

• 128883-48-7 6-(4-chlorophenyl)-2-oxo-6-(4-tolyl)-2,3,4,5-tetrahydro-3-pyridinecarboxamide 
• 132577-28-7 1-acetyl-3-(4-chlorophenyl)-5-(4-methylphenyl)-2-pyrazoline 
• 97691-62-8 6-(4-Chloro-phenyl)-4-p-tolyl-1H-pyrimidin-2-one 
• 127394-76-7 6-(4-Chloro-phenyl)-2-methoxy-4-p-tolyl-nicotinonitrile 
• 127394-67-6 6-(4-Chloro-phenyl)-2-ethoxy-4-p-tolyl-nicotinonitrile 
• 848089-61-2 2-[3-(4-Chloro-phenyl)-3-oxo-1-p-tolyl-propyl]-malonic acid diethyl ester 
• 101272-32-6 2,3-dibromo-1-(4-chloro-phenyl)-3-p-tolyl-propan-1-one 
• 622-47-9 4-tolylacetic acid 
• 74-11-3 para-chlorobenzoic acid 
• 110220-77-4 p-tolyl-3-(4-chlorophenyl)oxiran-2-yl-methanone 
• 1132907-14-2 (4-chlorophenyl)(2-(4-chlorophenyl)-2-hydroxy-4,5-di-p-tolylcyclopentyl)methanone 
• 1027736-78-2 1-(4-chlorophenyl)-3-(1H-indol-3-yl)-3-(4-methylphenyl)propan-1-one 
• 1217356-40-5 7-(4-chlorophenyl)-1,3-dimethyl-5-p-tolylpyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione 
• 1198089-02-9 C₃₅H₃₀ClFN₂ 

Relevant articles and documents

Design and synthesis of quinoline-pyrimidine inspired hybrids as potential plasmodial inhibitors

Presently, artemisinin-based combination therapy (ACT) is the first-line therapy of Plasmodium falciparum malaria. With the emergence of malaria parasites that are resistant to ACT, alternative antimalarial therapies are urgently needed. In line with this

Bu4NHSO4-Catalyzed Direct N-Allylation of Pyrazole and its Derivatives with Allylic Alcohols in Water: A Metal-Free, Recyclable and Sustainable System

Allylic amines are valuable and functional building blocks. Direct N-allylation of pyrazole and its derivatives as an atom economic strategy to provide allylic amines has been achieved only using commercial Bu4NHSO4 as the metal-free catalyst and water as the solvent without any additives. 11–93% isolated yields were obtained for the N-allylation of pyrazole and its derivatives with allylic alcohols. Bu4NHSO4 could be reused for six times by simple extraction nearly without loss of catalytic activity and was also suitable for a gram-scale production. The reaction of allylic ether and pyrazole did not occur to give the desired product indicated that allylic ether was not the active intermediate in the pathway. Density functional theory (DFT) calculations reveal that there are hydrogen bonding effects among substrates, solvent and catalyst, especially the one formed between allylic alcohol and H2O. Control experiments in different protic solvents further demonstrate the intermolecular hydrogen bonding of allylic alcohol and water. (Figure presented.).

Antiproliferative effects of chalcones on T cell acute lymphoblastic leukemia-derived cells: Role of PKCβ

In this study, a series of 20 chalcone derivatives was synthesized, and their antiproliferative activity was tested against the human T cell acute lymphoblastic leukemia-derived cell line, CCRF-CEM. On the basis of the structural features of the most active compounds, a new library of chalcone derivatives, according to the structure–activity relationship design, was synthesized, and their antiproliferative activity was tested against the same cancer cell line. Furthermore, four of these derivatives (compounds 3, 4, 8, 28), based on lower IC50 values (between 6.1 and 8.9 μM), were selected for further investigation regarding the modulation of the protein expression of RACK1 (receptor for activated C kinase), protein kinase C (PKC)α and PKCβ, and their action on the cell cycle level. The cell cycle analysis indicated a block in the G0/G1 phase for all four compounds, with a statistically significant decrease in the percentage of cells in the S phase, with no indication of apoptosis (sub-G0/G1 phase). Compounds 4 and 8 showed a statistically significant reduction in the expression of PKCα and an increase in PKCβ, which together with the demonstration of an antiproliferative role of PKCβ, as assessed by treating cells with a selective PKCβ activator, indicated that the observed antiproliferative effect is likely to be mediated through PKCβ induction.